These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2859172)

  • 1. Metabolic disposition of 2-chloroethyl nitrosocarbamoylcystamine in rats.
    Godeneche D; Madelmont JC; Moreau MF; Duprat J; Chabard JL; Plagne R; Meyniel G
    Drug Metab Dispos; 1985; 13(2):220-6. PubMed ID: 2859172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of 2-chloroethyl nitrosocarbamoylcystamine by rat liver subcellular fractions.
    Godeneche D; Madelmont JC; Moreau MF; Duprat J; Plagne R; Meyniel G
    Drug Metab Dispos; 1986; 14(1):112-7. PubMed ID: 2868853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and metabolism in 1-(2-chloroethyl)-3-(2',3',4'-tri-o-acetyl, ribopyranosyl)-1-nitrosourea in rats.
    Godeneche D; Moreau MF; Madelmont JC; Duprat J; Plagne R
    Cancer Res; 1982 Feb; 42(2):525-9. PubMed ID: 6799188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat.
    Patel DK; Woolley JL; Shcokcor JP; Johnson RL; Taylor LC; Sigel CW
    Drug Metab Dispos; 1991; 19(2):491-7. PubMed ID: 1676660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of the carcinostatic agent 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha,beta-d-ribofuranosyl]-1-nitrosourea in animals.
    Godenèche D; Madelmont JC; Moreau MF; Montoloy D; Plagne R
    Cancer Res; 1980 Sep; 40(9):3351-6. PubMed ID: 7427947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytostatic action of two nitrosoureas derived from cysteamine.
    Bourut C; Chenu E; Godenèche D; Madelmont JC; Maral R; Mathé G; Meyniel G
    Br J Pharmacol; 1986 Nov; 89(3):539-46. PubMed ID: 3801787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition and metabolism of a novel antineoplastic agent, 4-tert-butyl-[3-(2-chloroethyl)ureido]benzene, in mice.
    Maurizis JC; Rapp M; Azim EM; Gaudreault RC; Veyre A; Madelmont JC
    Drug Metab Dispos; 1998 Feb; 26(2):146-51. PubMed ID: 9456301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological disposition of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in mice.
    Rahman A; Luc PV; Schein PS; Woolley PV
    Cancer Res; 1984 Jan; 44(1):149-53. PubMed ID: 6690033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
    Emary WB; Toren PC; Mathews B; Huh K
    Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans.
    Ames MM; Kovach JS; Rubin J
    Cancer Res; 1984 Sep; 44(9):4151-6. PubMed ID: 6744326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Main metabolites of 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea and 1-(2-chloroethyl)-3-(2',3', 4'-tri-O-acetyl-alpha, beta-D-ribopyranosyl)-1-nitrosourea in rats.
    Madelmont JC; Moreau MF; Godeneche D; Duprat J; Plagne R; Meyniel G
    Drug Metab Dispos; 1982; 10(6):662-6. PubMed ID: 6130919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution, excretion, and metabolism of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea (ACNU) in rats and mice after iv administration.
    Tanaka M; Nishigaki T; Nakajima E; Totsuka S; Nakamura K
    Cancer Treat Rep; 1980; 64(4-5):575-80. PubMed ID: 6933003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of [14C]velnacrine maleate in rats, dogs, and humans.
    Turcan RG; Hillbeck D; Hartley TE; Gilbert PJ; Coe RA; Troke JA; Vose CW
    Drug Metab Dispos; 1993; 21(6):1037-47. PubMed ID: 7905382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.
    Blum W; Aichholz R; Ramstein P; Kühnöl J; Brüggen J; O'Reilly T; Flörsheimer A
    Rapid Commun Mass Spectrom; 2001; 15(1):41-9. PubMed ID: 11135423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and metabolism of sodium 4-[(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl]-gamma -oxobenzenebutanoate in rats and dogs.
    Tocco DJ; deLuna FA; Duncan AE; Ramjit HG; Pitzenberger SM; Hsieh JY
    Drug Metab Dispos; 1988; 16(5):690-6. PubMed ID: 2906591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of ivermectin in tissues of cattle, sheep, and rats.
    Chiu SH; Sestokas E; Taub R; Buhs RP; Green M; Sestokas R; Vandenheuvel WJ; Arison BH; Jacob TA
    Drug Metab Dispos; 1986; 14(5):590-600. PubMed ID: 2876867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection.
    Císar P; Nobilis M; Vybíralová Z; Holcapek M; Kolárová L; Pour M; Kunes J; Klimes J
    J Pharm Biomed Anal; 2005 Apr; 37(5):1059-71. PubMed ID: 15862686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
    Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
    Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.